


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
DATA FROM PHASE I CLINICAL STUDY OF TQB6411 “EGFR/C-MET ADC”
PRESENTED AT 2026 ASCO

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the data from a Phase I first-in-human study of TQB6411 “EGFR/c-Met ADC”, an investigational national Category 1 innovative drug independently developed by the Group’s subsidiary, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (“**CTTQ**”), in patients with advanced solid tumours, was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

As of 31 December 2025, a total of 26 patients were enrolled in this study (NCT07043751), with a median age of 60 (ranging from 33 to 75 years old), of whom 46.2% were female. All enrolled patients had advanced malignant tumours that had failed or were intolerant to standard-of-care therapy, including non-small cell lung cancer (NSCLC; n=21), esophageal cancer (n=3) and colorectal cancer (n=2). All patients had received at least one prior line of systemic therapy.

As of 13 January 2026, doses had been escalated from the initial level of 0.8 mg/kg to 6.6 mg/kg across five dose levels, with no dose-limiting toxicities (DLTs) observed. In the ≥ 4 mg/kg dose groups, among 9 patients who underwent at least one imaging assessment, 4 patients achieved partial response (PR), resulting in an objective response rate (ORR) of 44.4% and a disease control rate (DCR) of 100%. In particular, in the 5.3 mg/kg group, one NSCLC patient who had received two prior lines of therapy achieved a 55.2% reduction from baseline in targeted lesions; in the 4.0 mg/kg group, two NSCLC patients who had received three or more prior lines of therapy achieved reductions of 30.4% and 48.1% in targeted lesions, respectively, demonstrating robust anti-tumor activity in heavily pretreated patients with advanced tumours. In terms of safety, among 23 patients with at least 21 days of follow-up, the incidence of Grade 3 treatment-related adverse event (TRAEs) was 21.7%, and no Grade ≥ 4 TRAEs were observed across the overall population. In respect of the pulmonary toxicity, no interstitial lung disease (ILD) was reported during the study.

The study demonstrated that TQB6411 has a favourable safety profile at effective doses, particularly in terms of its low haematological toxicity. TQB6411 exhibits a stronger binding affinity for c-Met than for EGFR, with a potency ratio of 1:2. Such characteristic enhances the killing effect of TQB6411 on tumour cells with high c-Met expression, while mitigating EGFR-mediated adverse events, such as skin toxicity.

The overexpression of the epidermal growth factor receptor (EGFR) and the hepatocyte growth factor receptor (c-Met) is common in various solid tumours, including NSCLC, esophageal cancer, and colorectal cancer. Upon EGFR pathway blockade, tumour cells often switch to activate the c-Met pathway to bypass inhibition. Such mechanism is widely recognised as one of the core drivers of resistance to existing EGFR-targeted therapies.

As one of the first EGFR/c-Met ADCs worldwide to report clinical data, TQB6411 leverages a well-established target combination and a c-Met biased affinity design, thereby reducing development risks while establishing a differentiated competitive edge. The Phase I data presented demonstrates tumour regression at low doses in heavily pretreated patients with advanced tumours, accompanied by a favourable safety profile. Based on the abovementioned, the Group is expediting the clinical development of this drug.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 1 June 2026

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.